Nallamothu, Brahmajee K <br/><br/>
Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial.  [electronic resource] 

 -  European heart journal  Aug 2005 
 - 1506-12 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0195-668X 
<br/><br/><label>Standard No.: </label>10.1093/eurheartj/ehi181  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abciximab<br/>Adult<br/>Aged<br/>Angina Pectoris--drug therapy<br/>Antibodies, Monoclonal--administration & dosage<br/>Anticoagulants--administration & dosage<br/>Bundle-Branch Block--drug therapy<br/>Coronary Restenosis--etiology<br/>Coronary Stenosis--drug therapy<br/>Drug Therapy, Combination<br/>Female<br/>Fibrinolytic Agents--administration & dosage<br/>Hemorrhage--chemically induced<br/>Humans<br/>Immunoglobulin Fab Fragments--administration & dosage<br/>Injections, Intravenous<br/>Male<br/>Middle Aged<br/>Myocardial Infarction--etiology<br/>Partial Thromboplastin Time--mortality<br/>Recombinant Proteins--administration & dosage<br/>Recurrence<br/>Regression Analysis<br/>Survival Analysis<br/>Tissue Plasminogen Activator--administration & dosage<br/>Treatment Outcome